Welcome to our team JCO Page! Team JCO is once again organizing a team for the annual Multiple Myeloma event at Magnuson Park which takes place on Sunday, June 29th. When I got diagnosed, they told me I was probably looking at a five-to-seven-year life span. Thankfully, with newer treatments, and my body’s response, I will hit the eleven-year mark next week!
Everyone has been supportive of me for so long. Rather than continue to ask for donations, we just hope you might consider signing up again for the walk/run. It is a great time to see everyone & get together. I wouldn’t trade my family and friends for anything in this world. It has been a great ride, and hope it continues for a long time to come. On a personal level, I am still doing very well and hope to continue riding my present treatment indefinitely. I still wonder why I have been so fortunate to date. For everyone fighting cancer or an illness, keep the faith. I know the burden you carry every day, and it is a heavy one.
Thanks again to all my supporters!
Jeff
Please join us in this fight and increase our impact by making a donation to our team today; 100% of all funds raised will go directly to advancing multiple myeloma cancer research at Fred Hutchinson Cancer Research Center.
What is Multiple Myeloma?
Multiple Myeloma is a cancer of plasma cells found in bone marrow. Normal plasma cells help the immune system fight disease, but when plasma cells become cancerous they grow out of control and can produce a tumor called a plasmacytoma. If someone has more than one plasmacytoma, they have multiple myeloma.
Why support this event?
Defeat Multiple Myeloma’s mission is to raise awareness of multiple myeloma while supporting research that seeks to discover new treatments, improve the quality of life for myeloma patients, and ultimately find a cure for this devastating form of cancer. Funds from the 2025 Defeat Multiple Myeloma event will continue to support immunotherapy research and clinical trials at Fred Hutch which are using CAR-T cells and have shown very promising early results for patients.
